Our extensive scientific and clinical assessment program continues even after our products are placed on the market.

Long-term assessment and post-market studies will confirm whether the smoke-free products actually present less risk of developing smoking-related diseases than continued smoking and positively impact public health.

Overall, post-market studies will demonstrate how consumers use the products, if they switch partially or fully, and what is the potential level of initiation with our products. All of these elements are important for understanding the likely benefits of smoke-free products on population health.

We have also developed a comprehensive post-market surveillance program for consumers to report any health-related adverse events associated with the use of our products.  This information is regularly analyzed to identify any potential safety concerns and, if so, to report them to the regulatory authorities.

 

 

 

 

Our Network

We have a global network of research partners and our R&D facilities are located in Switzerland and Singapore.

Explore our network